Product class: Authorized package
Medicinal product class: For human use
Package code: 1835816
Name of medicinal product: BENDAMUSTINE BOSTON BIOPHARMA
Active substances:
Estonian, English, Latin
ATC code: L01AA09
Dosage form: powder for concentrate for solution for infusion
Route of administration: intravenous use
Strengh: 2,5mg 1ml
Amount in package: 25mg 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate. Indolent non-Hodgkin’s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.
Safety features: Yes
Summary of product characteristics (SPC):  (last updated 05 September 2022)
Package information leaflet (PIL): EST  (last updated 05 September 2022)
Labelling:  (last updated 05 September 2022)
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: Boston Biopharma LT UAB 
Marketing authorization number: 1070222 
Marketing authorization issued on: 05 September 2022 
Marketing authorization expires on: 05 September 2027 
Marketing authorization procedure type: Decentralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: 05 September 2022
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription